These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 34001867)

  • 1. Phase I/II trial of lenalidomide, methotrexate, leucovorin, cytarabine, and rituximab (LeMLAR) in relapsed or refractory diffuse large B cell lymphoma.
    Dührsen U; Tometten M; Kroschinsky F; Ganser A; Ibach S; Bertram S; Hüttmann A
    Blood Cancer J; 2021 May; 11(5):95. PubMed ID: 34001867
    [No Abstract]   [Full Text] [Related]  

  • 2. Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non-germinal center B-cell-like DLBCL.
    Goy A; Ramchandren R; Ghosh N; Munoz J; Morgan DS; Dang NH; Knapp M; Delioukina M; Kingsley E; Ping J; Beaupre DM; Neuenburg JK; Ruan J
    Blood; 2019 Sep; 134(13):1024-1036. PubMed ID: 31331917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 1b study from GELTAMO group.
    Martín A; Redondo AM; Dlouhy I; Salar A; González-Barca E; Canales M; Montes-Moreno S; Ocio EM; López-Guillermo A; Caballero D;
    Br J Haematol; 2016 Apr; 173(2):245-52. PubMed ID: 26847165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab, lenalidomide, and ibrutinib in relapsed/refractory primary cutaneous diffuse large B-cell lymphoma, leg type.
    Moore DC; Soni AC; Hu B; Smith ET; Levine J; Moyo TK; Jacobs R; Ghosh N; Park SI
    Br J Haematol; 2022 Feb; 196(4):e30-e33. PubMed ID: 34642938
    [No Abstract]   [Full Text] [Related]  

  • 5. Ibrutinib plus rituximab and lenalidomide for primary intestinal diffuse large B-cell lymphoma relapsed after anti-CD19 CAR-T cell therapy: a case report.
    Li C; Zhang X; Zhu D; Bu X; Wang L; Zhao P
    Ann Hematol; 2023 Dec; 102(12):3625-3627. PubMed ID: 37608197
    [No Abstract]   [Full Text] [Related]  

  • 6. AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma.
    Leonard JP; Trneny M; Izutsu K; Fowler NH; Hong X; Zhu J; Zhang H; Offner F; Scheliga A; Nowakowski GS; Pinto A; Re F; Fogliatto LM; Scheinberg P; Flinn IW; Moreira C; Cabeçadas J; Liu D; Kalambakas S; Fustier P; Wu C; Gribben JG;
    J Clin Oncol; 2019 May; 37(14):1188-1199. PubMed ID: 30897038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I/II trial to evaluate the safety, feasibility and activity of salvage therapy consisting of the mTOR inhibitor Temsirolimus added to standard therapy of Rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse large cell B-Cell lymphoma - the STORM trial.
    Witzens-Harig M; Memmer ML; Dreyling M; Hess G
    BMC Cancer; 2013 Jun; 13():308. PubMed ID: 23799873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial.
    Wang M; Fowler N; Wagner-Bartak N; Feng L; Romaguera J; Neelapu SS; Hagemeister F; Fanale M; Oki Y; Pro B; Shah J; Thomas S; Younes A; Hosing C; Zhang L; Newberry KJ; Desai M; Cheng N; Badillo M; Bejarano M; Chen Y; Young KH; Champlin R; Kwak L; Fayad L
    Leukemia; 2013 Sep; 27(9):1902-9. PubMed ID: 23545991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Société Française d'Oncologie Pédiatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia.
    Patte C; Auperin A; Michon J; Behrendt H; Leverger G; Frappaz D; Lutz P; Coze C; Perel Y; Raphaël M; Terrier-Lacombe MJ;
    Blood; 2001 Jun; 97(11):3370-9. PubMed ID: 11369626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma.
    Feldman T; Mato AR; Chow KF; Protomastro EA; Yannotti KM; Bhattacharyya P; Yang X; Donato ML; Rowley SD; Carini C; Valentinetti M; Smith J; Gadaleta G; Bejot C; Stives S; Timberg M; Kdiry S; Pecora AL; Beaven AW; Goy A
    Br J Haematol; 2014 Jul; 166(1):77-83. PubMed ID: 24661044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II study of lenalidomide and rituximab (R2) combination in patients with high-risk refractory/relapsed diffuse large B-cell lymphoma.
    Noel R; Zemmour C; Montes de Oca C; Belmecheri N; Aurran-Schleinitz T; Coso D; Lopez Almeida L; Mescam L; Vey N; Bladé JS; Slama B; Bouabdallah R; Schiano de Colella JM
    Hematology; 2023 Dec; 28(1):2207948. PubMed ID: 37133334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study.
    Salles G; Duell J; González Barca E; Tournilhac O; Jurczak W; Liberati AM; Nagy Z; Obr A; Gaidano G; André M; Kalakonda N; Dreyling M; Weirather J; Dirnberger-Hertweck M; Ambarkhane S; Fingerle-Rowson G; Maddocks K
    Lancet Oncol; 2020 Jul; 21(7):978-988. PubMed ID: 32511983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab-lenalidomide-dexamethasone induces complete and durable remission in relapsed refractory diffuse large B-cell non-Hodgkin lymphoma.
    Ivanov V; Tabouret E; Chuto G; Chetaille B; Fezoui H; Coso D; Rey J; Aurran-Schleinitz T; Schiano JM; Stoppa AM; Blaise D; Bouabdallah R
    Leuk Lymphoma; 2010 Sep; 51(9):1758-60. PubMed ID: 20629527
    [No Abstract]   [Full Text] [Related]  

  • 14. Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma.
    Oki Y; Westin JR; Vega F; Chuang H; Fowler N; Neelapu S; Hagemeister FB; McLaughlin P; Kwak LW; Romaguera JE; Fanale M; Younes A; Rodriguez MA; Orlowski RZ; Wang M; Ouzounian ST; Samaniego F; Fayad L
    Br J Haematol; 2013 Dec; 163(5):611-20. PubMed ID: 24117234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of lenalinomide combined with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma.
    Ivanov V; Coso D; Chetaille B; Esterni B; Olive D; Aurran-Schleinitz T; Schiano JM; Stoppa AM; Broussais-Guillaumot F; Blaise D; Bouabdallah R
    Leuk Lymphoma; 2014 Nov; 55(11):2508-13. PubMed ID: 24506467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab, bendamustine and cytarabine (R-BAC) in patients with relapsed-refractory aggressive B-cell lymphoma.
    Tisi MC; Paolini R; Piazza F; Ravelli E; Tecchio C; Sartori R; Famengo B; D'Amore ESG; Carli G; Perbellini O; Di Bona E; Ruggeri M; Visco C
    Am J Hematol; 2018 Dec; 93(12):E386-E389. PubMed ID: 30184246
    [No Abstract]   [Full Text] [Related]  

  • 17. Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.
    Smith SM; Pitcher BN; Jung SH; Bartlett NL; Wagner-Johnston N; Park SI; Richards KL; Cashen AF; Jaslowski A; Smith SE; Cheson BD; Hsi E; Leonard JP
    Lancet Haematol; 2017 Apr; 4(4):e176-e182. PubMed ID: 28314699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma.
    Wang M; Fayad L; Cabanillas F; Hagemeister F; McLaughlin P; Rodriguez MA; Kwak LW; Zhou Y; Kantarjian H; Romaguera J
    Cancer; 2008 Nov; 113(10):2734-41. PubMed ID: 18973182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect and Safety of Orelabrutinib and Lenalidomide Plus R-mini CDOP in Relapsed/Refractory Aggressive B-cell Non-Hodgkin Lymphoma.
    Shang Y; Zhao H; Li D
    Turk J Haematol; 2023 Dec; 40(4):284-285. PubMed ID: 37656047
    [No Abstract]   [Full Text] [Related]  

  • 20. Complete metabolic remission in an 84-year old patient with relapsed/refractory diffuse large B-cell lymphoma following combination immunotherapy with lenalidomide plus rituximab.
    Tomuleasa C; Iluta S; Pasca S; Roman A; Piciu D; Jitaru C; Teodorescu P; Rus I; Bojan A; Dima D; Zdrenghea M; Petrushev B
    Int J Hematol; 2020 Oct; 112(4):597-598. PubMed ID: 32886277
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.